Vincerx Pharma To Present Three Posters at ASH 2023 in December

VIP943 poster supports selectivity and safety of lead CD123 ADC, VIP943, currently in Phase 1

VIP924 poster shows this novel CXCR5-ADC compares favorably with other ADCs in clinical development

Enitociclib poster expands potential clinical indications

PALO ALTO, Calif., Nov. 02, 2023 (GLOBE NEWSWIRE) -- Vincerx Pharma, Inc. (Nasdaq: VINC)(“Vincerx”), a biopharmaceutical company aspiring to address the unmet medical needs of patients with cancer through paradigm-shifting therapeutics, today announced that it will present three posters related to VIP943 (NCT06034275), VIP924 (in preclinical studies), and enitociclib (in collaboration with University of Calgary) at the 65^th American Society for Hematology Meeting (ASH), taking place in San Diego California from December 9 to 12, 2023.

"The three ASH 2023 posters highlight the strong scientific foundation for Vincerx’s programs. We look forward to providing new data on the robust preclinical activity of our lead antibody-drug conjugate (ADC), VIP943, which recently began enrolling patients with relapsed/refractory acute myeloid leukemia (R/R AML), myelodysplastic syndrome (MDS), and B-cell acute lymphoblastic leukemia (B-cell ALL),” said Ahmed Hamdy, M.D., Chief Executive Officer of Vincerx. “In addition, we are pleased to share preclinical data related to the activity of VIP924, a first-in-class CXCR5 ADC for the treatment of B-cell malignancies. Also, in collaboration with University of Calgary, we show enitociclib’s preclinical activity in pediatric leukemia.”

Poster Presentation Information:

Title: Selectivity and Safety of VIP943: A Novel CD123-Targeting Antibody-Drug Conjugate (ADC) Using a Proprietary Linker and Payload Class 
Session Name: 604. Molecular Pharmacology and Drug Resistance: Myeloid Neoplasms: Poster I 
Session Date: Saturday, December 9, 2023 
Presentation Time: 5:30 PM - 7:30 PM, Pacific Standard Time 
Location: San Diego Convention Center, Halls G-H
Publication Number: 1435 
Presented by Beatrix Stelte-Ludwig, Vincerx Pharma

Title: Comparison of the CXCR5-Antibody Drug Conjugate (ADC; VIP924) to a CD19-ADC and a CD79b-ADC in a Humanized Rec-1 Mantle Cell Lymphoma (MCL) Mouse Model 
Session Name: 605. Molecular Pharmacology and Drug Resistance: Lymphoid Neoplasms: Poster II 
Session Date: Sunday, December 10, 2023 
Presentation Time: 6:00 PM - 8:00 PM, Pacific Standard Time 
Location: San Diego Convention Center, Halls G-H
Publication Number: 2809 
Presented by Tibor Schomber, Vincerx Pharma

Title: Targeting CDK9 in KMT2A-Rearranged Infant Leukemia: Evidence for Activity and Drug Synergy with Enitociclib